Atopic Dermatitis

New results of the phase 3 ECZTRA 6 trial, evaluating tralokinumab for pediatric patients with eczema, found that the drug was superior to placebo in the primary and secondary endpoints.

Expert dermatologists review the impact of atopic dermatitis on quality of life for both the patient and their families.

Peter A. Lio, MD, provides an overview of the pathophysiology of atopic dermatitis (AD) and the comorbidities often associated with it.

In recently-presented data, ivarmacitinib was found to have decreased severity of moderate-to-severe eczema compared to placebo.

New late-breaking data supported prior results indicating that all primary and secondary endpoints were reached for the IL-4Rα antibody known as CBP-201 for atopic dermatitis patients.

Late-breaking data on roflumilast cream for eczema patients in two phase 3 trials titled INTEGUMENT-1 and INTEGUMENT-2 showed strong results for the drug.

In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

New phase 3 trial data was announced by Dermavant Sciences indicating strong results for both efficacy and safety of tapinarof treatment for atopic dermatitis.

Experts in dermatology share advice on helping fellow physicians stay apprised of the advances in AD and treat their patients more effectively.

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Drs Raj Chovatiya, George Han, and Vivian Shi review the current challenges and opportunities surrounding the utilization and availability of biologic therapies in atopic dermatitis.

Expert dermatologists highlight the burden of atopic dermatitis in young children and examine the clinical data for dupilumab, a biologic treatment for this age group.

The expert panel discusses the heterogeneity of atopic dermatitis manifestation and therapy decisions for individual patients.

Dr Vivian Shi provides an overview of treatment options for atopic dermatitis patients in different age groups.

A new post-hoc analysis used 5 clinical trials on dupilumab to assess the drug’s effectiveness with and without topical corticosteroids for atopic dermatitis/eczema patients.

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.